These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24671905)

  • 1. A new toolkit for conducting clinical trials in rare disorders: will this dog hunt?
    Peterson RG; Macleod SM; Klein AV
    J Popul Ther Clin Pharmacol; 2014; 21(1):e79-80. PubMed ID: 24671905
    [No Abstract]   [Full Text] [Related]  

  • 2. A new toolkit for conducting clinical trials in rare disorders.
    Abrahamyan L; Diamond IR; Johnson SR; Feldman BM
    J Popul Ther Clin Pharmacol; 2014; 21(1):e66-78. PubMed ID: 24671886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
    Picavet E; Cassiman D; Pinxten W; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials of orphan medicines.
    Buckley BM
    Lancet; 2008 Jun; 371(9629):2051-5. PubMed ID: 18555919
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuromuscular disorders: orphan diseases deserve attention.
    de Visser M
    Lancet Neurol; 2006 Jan; 5(1):13-4. PubMed ID: 16361013
    [No Abstract]   [Full Text] [Related]  

  • 6. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug labels: a flawed source of data for studying orphan drug approvals.
    Kesselheim AS; Avorn J
    Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
    [No Abstract]   [Full Text] [Related]  

  • 9. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
    Macleod S; Lasko P; Mackenzie A
    J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan drugs: Indian perspective.
    Kumar H; Sarma P; Medhi B
    Indian J Pharmacol; 2017; 49(4):267-269. PubMed ID: 29326485
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA program could boost treatments for neglected diseases.
    Traynor K
    Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
    [No Abstract]   [Full Text] [Related]  

  • 13. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 15. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

  • 16. Increasing the use of orphan drugs in clinical practice.
    Hulton SA; Greener M
    Hosp Med; 2004 Jul; 65(7):400-3. PubMed ID: 15287343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human-on-a-chip approach to tackling rare diseases.
    de Mello CPP; Rumsey J; Slaughter V; Hickman JJ
    Drug Discov Today; 2019 Nov; 24(11):2139-2151. PubMed ID: 31412288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orphan drug designation and development in Japan: 25 years of experience and assessment.
    Sakushima K; Takeda H; Aoi Y
    Nat Rev Drug Discov; 2021 Dec; 20(12):893-894. PubMed ID: 33723413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.